The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells

Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells

(2015) Roya Navab et al.   NEOPLASIA

A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties

(2013) James M. Murphy et al.   BIOCHEMICAL JOURNAL

EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis

(2013) J. L. Breindel et al.   CANCER RESEARCH

Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis

(2013) B. Cui et al.   CANCER RESEARCH

Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family

(2012) Stephen C. Artim et al.   BIOCHEMICAL JOURNAL

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

(2012) Vincent T. Bicocca et al.   CANCER CELL

NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma

(2012) Tomoya Yamaguchi et al.   CANCER CELL

The role of pseudokinases in cancer

(2012) Hua Zhang et al.   CELLULAR SIGNALLING

Differential regulation of axonal growth and neuromuscular junction assembly by HGF/c-Met signaling

(2012) Pan P. Li et al.   DEVELOPMENTAL DYNAMICS

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy

(2012) Guilly Rebagay et al.   Frontiers in Oncology

Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis

(2011) A. Gentile et al.   CANCER RESEARCH

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells

(2010) Aniruddha Choudhury et al.   BRITISH JOURNAL OF HAEMATOLOGY

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors

(2010) A. Bertotti et al.   CLINICAL CANCER RESEARCH

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

RNAi screen for rapid therapeutic target identification in leukemia patients

(2009) J. W. Tyner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

(2009) A. Bertotti et al.   Science Signaling

The Met tyrosine kinase receptor in development and cancer

(2008) Alessandra Gentile et al.   CANCER AND METASTASIS REVIEWS

Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells

(2008) K. L. Mueller et al.   CANCER RESEARCH

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

(2008) S. Baskar et al.   CLINICAL CANCER RESEARCH

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

(2008) Amir H. DaneshManesh et al.   INTERNATIONAL JOURNAL OF CANCER

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

The Deleted in Brachydactyly B Domain of ROR2 Is Required for Receptor Activation by Recruitment of Src

(2008) Shiva Akbarzadeh et al.   PLoS One

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

(2008) T. Fukuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA